The Brief
Feb. 25, 2015

American Society of Clinical Oncology endorses American Cancer Society Prostate Cancer Survivorship Care Guidelines
Prostate Cancer News Today
In the United States, according to recent estimations, nearly 3 million men have prostate cancer, and approximately 233,000 patients are expected to be diagnosed in 2014. Prostate cancer accounts for 20 percent of all cancer survivors in the U.S., and although there are guidelines addressing prostate cancer screening and treatment, they still need to be structured to optimize the survivorship experience of patients who have been treated for this disease.More

Screening for psychosocial distress: A review
Oncology Nurse Advisor
A cancer diagnosis is often accompanied by many unanswered questions and concerns, leading to one of the most underestimated effects of cancer: psychosocial distress. In addition to personal and financial concerns, side effects of the disease and treatments can exacerbate the symptoms of distress. Distress is defined as "a multifactorial unpleasant emotional experience of a psychological, social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment."More

Heart health after cancer: A growing concern
Nearly 15 million people are living after a cancer diagnosis in the United States. This number represent over 4 percent of the population, an astonishing figure. And a growing one, as reported last year by the American Cancer Society and outlined by the National Cancer Institute's Office of Cancer Survivorship. As cancer patients survive longer they face additional health problems. Radiation to the chest, chemotherapy, antibody therapy and hormone changes can affect blood vessels and heart function in the short term and long, during treatment or years later. But millions affected — and their physicians — remain insufficiently mindful about the risk of heart disease.More

New screening tests for hard-to-spot breast cancers
The Wall Street Journal
Millions of women in 21 states will get an ominous note with their mammogram results this year. Even if everything seems fine, they'll be informed that they have dense breast tissue, which can raise their risk for cancer and hide abnormalities, making their mammograms less accurate. The question is: now what?More

Register now for the NCDB Workshop and Survey Savvy

The NCDB Workshop and Survey Savvy will be held in Chicago on June 17- 19. The NCDB workshop Maximizing NCDB Data to Improve Your Cancer Program will review the current uses and future updates for the National Cancer Data Base (NCDB) quality tools. Major NCDB quality tools will be reviewed with a focus on how the data can be used to inform decisions for cancer program administration and by cancer physicians. Learn about the uses for the cancer registry and how patient navigators can use the data .

Survey Savvy provides in-depth review of the information your cancer committee needs to coordinate a high-quality, patient-centered, multidisciplinary cancer program. Developed by CoC staff and CoC committee leadership, this program addresses your cancer programs' most common questions, issues, and concerns regarding CoC standards and compliance.

Whether your cancer program is preparing for a re-accreditation survey or looking for clarification on the standards, this program provides increased understanding of standard requirements and implementation. Through lectures, panel presentations, and the opportunity to meet and speak with experts, cancer program members will learn how to use the CoC standards as a framework to develop a comprehensive cancer care program that delivers high-quality and patient-centered care. Plan now to attend these meetings.More

Gene identified that lays foundation for pancreatic cancer
Medical News Today
A team of researchers have identified a gene that influences the shape of normal pancreatic cells and, as a result, could set the foundation for pancreatic cancer to develop. The study, published in Nature Communications, suggests that targeting the gene in question — protein kinase D1 — could lead to new ways of halting the development of one of the most difficult tumors to treat.More

Register now for Pursuing Excellence through NAPBC Accreditation

Plan now to join us on April 24 at the Westin Westminster Denver-Boulder Hotel for the National Accreditation Program for Breast Centers (NAPBC) Pursuing Excellence through NAPBC Accreditation workshop. Attending this program — taught by experienced NAPBC committee members, board members, surveyors and staff — will give you the knowledge to develop and operate a high-quality breast center and achieve and maintain NAPBC accreditation. Registration for this program is now open.More

Novartis blood cancer drug wins US OK after setback
The U.S. Food and Drug Administration recently approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval. The drug, Farydak, in clinical trials almost doubled to 10.6 months the amount of time it took for the disease to progress, compared with standard treatment. But it was associated with a wide array of serious side effects, including severe diarrhea and heart problems, which are prominently listed in a boxed warning.More

Five cancer detection tests for early prevention
There are powerful reasons that to many, cancer is the dreaded Big C. Everyone knows someone fighting a battle with cancer or who has died from it. While many diagnosed individuals live to tell their tale, there is that initial confrontation with mortality that can be hard to overcome. Fortunately, with the improvements in modern medicine, there are good cancer detection tests that should be part of routine screening.More